Your browser doesn't support javascript.
Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses.
Ithinji, Duncan G; Buchholz, David W; Ezzatpour, Shahrzad; Monreal, I Abrrey; Cong, Yu; Sahler, Julie; Bangar, Amandip Singh; Imbiakha, Brian; Upadhye, Viraj; Liang, Janie; Ma, Andrew; Bradel-Tretheway, Birgit; Kaza, Benjamin; Yeo, Yao Yu; Choi, Eun Jin; Johnston, Gunner P; Huzella, Louis; Kollins, Erin; Dixit, Saurabh; Yu, Shuiqing; Postnikova, Elena; Ortega, Victoria; August, Avery; Holbrook, Michael R; Aguilar, Hector C.
  • Ithinji DG; School for Global Animal Health, Washington State University, Pullman, WA, USA.
  • Buchholz DW; Kenya Agricultural and Livestock Research Organization, Nairobi, Kenya.
  • Ezzatpour S; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Monreal IA; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Cong Y; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Sahler J; National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Ft Detrick, Frederick, MD, 21702, USA.
  • Bangar AS; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Imbiakha B; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Upadhye V; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Liang J; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Ma A; National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Ft Detrick, Frederick, MD, 21702, USA.
  • Bradel-Tretheway B; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Kaza B; School for Global Animal Health, Washington State University, Pullman, WA, USA.
  • Yeo YY; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Choi EJ; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Johnston GP; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Huzella L; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Kollins E; National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Ft Detrick, Frederick, MD, 21702, USA.
  • Dixit S; National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Ft Detrick, Frederick, MD, 21702, USA.
  • Yu S; National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Ft Detrick, Frederick, MD, 21702, USA.
  • Postnikova E; National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Ft Detrick, Frederick, MD, 21702, USA.
  • Ortega V; National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Ft Detrick, Frederick, MD, 21702, USA.
  • August A; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Holbrook MR; Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
  • Aguilar HC; National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Ft Detrick, Frederick, MD, 21702, USA.
NPJ Vaccines ; 7(1): 166, 2022 Dec 17.
Article in English | MEDLINE | ID: covidwho-2185872
ABSTRACT
Experimental vaccines for the deadly zoonotic Nipah (NiV), Hendra (HeV), and Ebola (EBOV) viruses have focused on targeting individual viruses, although their geographical and bat reservoir host overlaps warrant creation of multivalent vaccines. Here we explored whether replication-incompetent pseudotyped vesicular stomatitis virus (VSV) virions or NiV-based virus-like particles (VLPs) were suitable multivalent vaccine platforms by co-incorporating multiple surface glycoproteins from NiV, HeV, and EBOV onto these virions. We then enhanced the vaccines' thermotolerance using carbohydrates to enhance applicability in global regions that lack cold-chain infrastructure. Excitingly, in a Syrian hamster model of disease, the VSV multivalent vaccine elicited safe, strong, and protective neutralizing antibody responses against challenge with NiV, HeV, or EBOV. Our study provides proof-of-principle evidence that replication-incompetent multivalent viral particle vaccines are sufficient to provide protection against multiple zoonotic deadly viruses with high pandemic potential.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2022 Document Type: Article Affiliation country: S41541-022-00588-5

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2022 Document Type: Article Affiliation country: S41541-022-00588-5